Just half of Americans know the five common heart attack symptoms—even when presented with the symptoms as “yes” or “no” answers—based on 2017 results from the National Health Interview Survey (NHIS).

A new study of young heart attack sufferers revealed a sobering, albeit unsurprising, finding: More than 90 percent had at least one modifiable risk factor. What’s equally concerning, according to the authors, is the prevalence of most of these risk factors increased over the decade-long study.

Biologic treatment favorably modifies coronary plaque characteristics for patients with severe psoriasis, suggests a study published Feb. 5 in Cardiovascular Research. The findings raise the possibility that the anti-inflammatory drugs can both treat psoriasis and reduce cardiovascular risk.

The incidence of acute myocardial infarction (AMI) in pregnant women increased between 2005 and 2014, according to research published in the American Journal of Cardiology Jan. 25, but that hike was accompanied by decreases in mortality, cost of care and length of stay among expectant mothers.

An extended analysis of the ODYSSEY OUTCOMES trial has confirmed alirocumab, a PCSK9 inhibitor that hit the medical market in 2015, reduces a patient’s total risk of nonfatal and fatal cardiovascular events after an acute coronary syndrome (ACS).

Archeologists have uncovered evidence of atherosclerosis in a handful of 500-year-old mummies from Greenland, Forbes reported.

Higher concentrations of troponin—even those that were within a “normal range”—signal increased odds of adverse outcomes among outpatients with stable chest pain, suggesting the biomarker test may improve risk stratification and inform management strategies for this common clinical scenario.

Research published in the Journal of the American Heart Association Jan. 13 has concluded administering PCSK9 inhibitors to acute MI patients ahead of ischemia can mitigate the potential negative neurological effects that come with treatment.